ASCO 2025

Practice changing results for EBC patients?

HRD and BRCA status as a new innovative staging system?

WSG: HER2+ pooled analysis

Intraoperative dose escalation helps to reach targeted…

TRADE: Abemaciclib in eBC

A new standard for endocrine-resistant HR+ MBC?

AI and ADCs: Precision diagnostics & safer rechallenge…

New compounds - new approaches: TNBC | HR+ | HER2+

SG + Pembro in aTNBC: a new standard of care?

A new standard for the firstline treatment of HER2+…

Next-gen endocrine therapies and ADCs: Updates from…

SERENA-6 - a challenging strategy?

Effective ADC for HER2+ mBC with brain metastases

Additional ADC effective for untreated TNBC

Final OS-Analysis of INAVO-120 trial

Liquid biopsy as a navigator for personalized therapy…

Sac-TMT for metastatic TNBC

Vepdegestrant for treatment of ER+/HER2- aBC

Future new SOC for PD-L1-positive mTNBC

New SOC in first-line treatment for primary endocrine…

Ipataserib + Fulvestrant improves PFS in PIK3CA-altered…

T-DXd: Detecting ILD and treat again

New firstline SOC for HER2+ metastatic BC

ASCENT-04

New AKT/PIK3 Antagonist for treatment of mBC after…

ABC for metastatic TNBC

New treatment option in first line of metastatic TNBC

SG + Pembrolizumab might become SOC for PD-L1-positive…

Re-exposition and ILD

A new first-line therapy for TNBC

Ipatasertib + Fulvestrant mejora la supervivencia libre…

SG + Pembrolizumab podría convertirse en el tratamiento…

Un nouveau traitement de première ligne pour le TNBC

Analisi finale della OS dello studio INAVO-120

Nuova opzione di trattamento in prima linea per il TNBC…

Vepdegestrant per il trattamento di ER+/HER2- aBC

Una nuova terapia di prima linea per il TNBC

A bright future? Radioligands, hormonal treatment…

The role of ARPIs in mHSPCThe role of ARPIs in mHSPC

MMAI Model identifies patients who benfit from ARPI in…

Personalized In Situ Immunotherapy SYNC-T Shows High…

Stereotactic beam radiation therapy 2.0

mHSPC - ADT + NHT updates

Niraparib + Abiraterone Improves Outcomes in…

Adding EZH2 to Enzalutamide to decrease the development…

New way of treatment for PCa

CAN-2409 Offers First New Option in 20 Years

Immuntherapy - an evolution?

Combination of LU-PSMA and immunotherapy, EVOLUTION…

mHSPC - prognostification - indications on integration?

Real world data from ironman registry confirms…

Localized CSPC - innovations

News of ANZUP trial

Real-world data från Ironman: PSA nivå en viktig…

Evolution: Kombination av LuPSMA och immunterapi.

Complete but Not Finished: EV+P cCR Data Extend the SOC…

ICI Combos in 1L and Maintenance – Mixed Bags or…

Sasanlimab + BCG: Practice-Changing Potential for…

A new prognostic factor in bladder cancer?: The case of…

CREST Study: Promising Results with PD-1 Inhibitor…

UTUC - enlighted

The role of sansalimab (+ SG) in BCG-naive and…

Response matters in advanced urothelial cancer patients…

NIAGARA study and circulating tumor DNA

Intensive caution of BCG Therapy

New option for high-risk NMIBC

Benefit of IO/IO therapy in mUC

Update on EV-PEM in the EV-302 study

mUC - new approaches?

New nectin-4 ADCs are coming

mUC EVP + subsequent therapies

De nouveaux ADC pour la nectine-4 arrivent

HIF alfa sigue siendo una diana interesante en el RCC y…

El rol de sansalimab (+ SG) en el carcinoma urotelial…

La respuesta es importante en pacientes con cáncer…

¿Un nuevo factor pronóstico en el cáncer de vejiga? El…

Who Really Benefits? Pembro’s Solid, Atezo’s Still…

9 Years of CheckMate 214 – Is Nivo + Ipi Still Holding…

Casdatifan + Cabo – Too Early to Call It a Game…

Long-term outcome of Nnivo-Ipi in clear cell RCC

HIF alpha still an interesting target in RCC and other…

5-Year OS data from the KEYNOTE-564 study

Zanzalitinib + Nivolumab +/- Relatlimab in Front-line…

First lession

Nivo + Ipi - Update & Insights

Neoadjuvant Approaches in resectable NSCLC: Insights…

Neoadjuvant Alectinib in resectable stage III NSCLC

MRD-analysis of the AEGEAN-trial

CheckMate 816: Update on OS-benefit

cTDNA in periop chemo-IO strategies

Chemoimmunotherapy followed by chemoradiotherapy

Neadjuvant targeted therapy

ctDNA stratification

CM-816: The OS results are positive and demonstrate…

CheckMate 816 : Mise à jour sur les avantages du…

CM-816 : Les résultats de l'OS sont positifs et…

Targeting rare mutations in metastatic NSCLC - HER2 and…

What is the future in the field of EGFR resistance?

TROP2 targets – where is first-line development…

Sevarbertinib – an additional option for HER2 exon 20…

GDPase-Inhibition 1st line in KRAS G12C Mut.: Improved…

KRAS G12C: Can immunotherapy improve patient outcome…

Benefit of IO is depending on the time of day of…

HERTHENA-Lung02 unfortunately negative study -…

Updates on ADCs in EGFR resistance

ADC in the 3L beats docetaxel

Have we MET our target?

Time of day of immunotherapy is important

HER3-DXd: dissapointing negative trial

ADC as 3L in EGFR

Does the timing of IO-infusion impact survival?

Immunotherapy – before or after 3 p.m.?

Is there still a place for HER3-DXd in advanced NSCLC?

KRAS G12C: Kan immunotherapie alleen het resultaat voor…

Hebben we ons doel gehaald?

Is er nog een plaats voor HER3-DXd in gevorderd NSCLC?

HERTHENA-Lung02 étude malheureusement négative -…

Taralatamb - the new SOC in 2L treatment

New maintenance therapy for SCLC

New therapies to improve patient survival

Tarlatamab - a new SOC in second line

The first positive maintenance therapy in SCLC

De nouvelles thérapies pour améliorer la survie des…

LA HNSCC - New neoadjuvant SOC